BriaCell Therapeutics Corp. (TSX: BCT)
Health Care · Biotechnology · CA
CA$5.56
+17.55% today · -46.6% 1Y
BriaCell Therapeutics Corp. (TSX: BCT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $35.13M and employs 17 people.
Over the last twelve months the share price has lost 46.6%, trading between 3.68 and 20.40.
Tweenvest scores BriaCell Therapeutics Corp. across four factors: quality 26/100. Its strongest factor is quality.
BCT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $35.13M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -9.66
- Dividend yield
- —
- Beta (5Y)
- 1.52
- 52-week high
- CA$20.40
- 52-week low
- CA$3.68
- Avg volume (3M)
- —
- Shares outstanding
- 8.70M
- Employees
- 17
- Next earnings
- —
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.
- ISIN
- CA1079303071
- Listed since
- Aug 13, 2012
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.